Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases | British Journal of Ophthalmology

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via AAO

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article metrics

Clinical science

Real-world experience of using ciclosporin-A 0.1% in the management of ocular surface inflammatory diseases

Online download statistics by month:

Online download statistics by month: March 2021 to March 2024

	Abstract	Full	Pdf
Mar 2021	1757	1744	1233
Apr 2021	1149	1149	783
May 2021	307	306	67
Jun 2021	246	247	47
Jul 2021	298	299	39
Aug 2021	358	361	52
Sep 2021	392	393	55
Oct 2021	440	451	67
Nov 2021	447	454	74
Dec 2021	445	450	26
Jan 2022	427	437	39
Feb 2022	486	482	56
Mar 2022	526	524	34
Apr 2022	424	420	44
May 2022	525	529	55
Jun 2022	872	878	188
Jul 2022	2060	2051	1068
Aug 2022	842	838	126
Sep 2022	359	348	61
Oct 2022	307	309	55
Nov 2022	295	281	36
Dec 2022	258	256	34
Jan 2023	220	222	46
Feb 2023	227	232	49
Mar 2023	266	263	54
Apr 2023	376	371	42
May 2023	540	543	82
Jun 2023	334	330	46
Jul 2023	321	322	47
Aug 2023	238	238	53
Sep 2023	280	283	35
Oct 2023	264	264	200
Nov 2023	313	306	291
Dec 2023	318	311	454
Jan 2024	193	170	567
Feb 2024	192	193	74
Mar 2024	236	234	75
Total	17538	17489	6354